BTIG analyst Thomas Shrader has maintained their bullish stance on PCVX stock, giving a Buy rating on December 8.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Thomas Shrader has given his Buy rating due to a combination of factors that highlight the promising potential of Vaxcyte’s VAX-31 vaccine. The pivotal Phase 3 trial for VAX-31 is designed to set a new standard for adult pneumococcal conjugate vaccines by comparing it directly with existing vaccines, Capvaxive and Prevnar 20. The trial’s robust design and the promising Phase 2 results suggest that VAX-31 could offer superior coverage against invasive pneumococcal disease and pneumonia, potentially providing greater protection than current vaccines.
Furthermore, the vaccine is expected to be recommended for adults over 50 and again at 65, which could lead to regular usage and strong market adoption. The trial’s success criteria, which include a noninferiority margin for immunogenicity, are strategically set to establish VAX-31 as a leading vaccine, potentially hindering future competitors. These factors, combined with a favorable valuation analysis, underpin Shrader’s positive outlook and Buy rating for Vaxcyte’s stock.
Shrader covers the Healthcare sector, focusing on stocks such as NRX Pharmaceuticals, Harrow Health, and Vaxcyte. According to TipRanks, Shrader has an average return of 4.7% and a 39.34% success rate on recommended stocks.
In another report released on December 8, Needham also maintained a Buy rating on the stock with a $90.00 price target.